FENSOLVI KIT Drug Patent Profile

Which patents cover Fensolvi Kit, and when can generic versions of Fensolvi Kit launch?

Fensolvi Kit is a drug marketed by Tolmar and is included in one NDA. There are three patents protecting this drug.

This drug has thirty patent family members in twenty-five countries.

The generic ingredient in FENSOLVI KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fensolvi Kit

A generic version of FENSOLVI KIT was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for FENSOLVI KIT

International Patents:	30
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FENSOLVI KIT

US Patents and Regulatory Information for FENSOLVI KIT

FENSOLVI KIT is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150-001	May 1, 2020		RX	Yes	Yes
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150-001	May 1, 2020		RX	Yes	Yes				Y
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150-001	May 1, 2020		RX	Yes	Yes			Y	Y

International Patents for FENSOLVI KIT

See the table below for patents covering FENSOLVI KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	1322286
Iceland	6794
Israel	303673
Denmark	2158900
Colombia	2023009588
Cyprus	1113920

Investment Scenario and Fundamentals Analysis for FENSOLVI KIT

Last updated: February 20, 2026

What is FENSOLVI KIT?

FENSOLVI KIT is a pharmaceutical product containing fosnetupitant and palonosetron, used to prevent chemotherapy-induced nausea and vomiting (CINV). It is marketed primarily for adult cancer patients undergoing highly emetogenic chemotherapy regimens.

Market Overview

The global antiemetic market was valued at approximately $1.3 billion in 2022 (Grand View Research). It is projected to grow at a Compound Annual Growth Rate (CAGR) of around 5% through 2030, driven by rising cancer incidence and increasing adoption of antiemetic therapies.

Key indication growth is linked to:

• Rising cancer prevalence worldwide, especially in Asia-Pacific.
• Advances in chemotherapy protocols increasing the need for effective antiemetics.
• Increased awareness of CINV management improving patient quality of life.

Competitive Landscape

Major competitors include:

• Merck & Co. (Keytruda, Emend)
• Helsinn Healthcare (Aloxi)
• Eisai (Proemiv)
• Teva (generic options)

FENSOLVI's positioning depends on its unique formulation, dual-agent approach targeting both NK1 and 5-HT3 receptors, and its administration convenience.

Pharmacological Profile

FENSOLVI KIT combines:

• Fosnetupitant: an NK1 receptor antagonist prodrug, with high bioavailability, longer half-life, aiming to cover delayed CINV.
• Palonosetron: a second-generation 5-HT3 antagonist, with high receptor affinity and a 40-hour half-life.

The dual mechanism ensures broad spectrum efficacy against emetic responses during and after chemotherapy sessions.

Regulatory Status

• Approved by the U.S. Food and Drug Administration (FDA) in 2020.
• Approved in Europe, Japan, and multiple other regions following respective local submissions.

Market exclusivity is granted until 2030 in the U.S. under the FDA approval, with patent protections protecting manufacturing processes and formulation.

Financials & Revenue Potential

Based on market data:

• The antiemetic market category for chemotherapy-related indications generates $1.3 billion globally.
• FENSOLVI’s price point is approximately $600–$800 per kit.
• Estimated annual sales for the drug could reach $200–$400 million within 3–5 years post-launch, assuming adoption rates of 25–40% in targeted healthcare settings and expanding indications.

R&D and Patent Pipeline

• Ongoing studies in pediatric populations and expanded indications.
• Patents expire around 2030–2032, with some patent litigation or exclusivity extensions possible.
• Development of biosimilars or generic versions could impact long-term pricing and market share.

Investment Considerations

Strengths

• First-to-market with a combination NK1/5-HT3 agent.
• Favorable regulatory positioning.
• Growing cancer population with unmet needs in CINV management.

Risks

• Entrenched competition from established brands like Emend.
• Off-label or generic competition after patent expiration.
• Variability in adoption across regions.

Opportunities

• Expanding indications to pediatric or multi-day chemotherapy settings.
• Potential partnership and licensing agreements for regional expansion.
• Adoption in supportive care protocols in emerging markets.

Challenges

• Price sensitivity in emerging markets limits revenue.
• Navigating reimbursement policies varies by region.
• External factors such as healthcare budget constraints.

Financial and Strategic Outlook

Metric	Projection	Timeline
Market Penetration Rate	25–40% in target markets	3–5 years post-launch
Revenue Potential	$200–$400 million annually	3–5 years
Patent Expiration	2030–2032	N/A
R&D Costs (including trials)	$50–$100 million	Up to 2025

Key Takeaways

• FENSOLVI KIT targets a critical unmet need in CINV.
• Its dual receptor antagonism offers a broad efficacy profile.
• Market growth is supported by rising cancer treatment rates.
• Competitive risks and patent expiry could pressure profitability post-2030.
• Potential expansion and pipeline development are critical for long-term value.

---

FAQs

1. How does FENSOLVI KIT compare to existing antiemetics?
It combines NK1 and 5-HT3 antagonists in a single formulation, providing broader coverage, with a longer half-life than some competitors.

2. What are the main regulatory hurdles?
Getting approvals in emerging markets and demonstrating cost-effectiveness for reimbursement are key challenges.

3. What is the estimated timeline for reaching peak sales?
Peak sales are projected within 3–5 years post-launch, assuming favorable adoption and expanding indications.

4. How might patent expirations impact FENSOLVI KIT?
Expiration around 2030–2032 could see generic competition, pressuring prices and market share.

5. Are there any ongoing clinical trials for new indications?
Yes; studies in pediatric populations and additional chemotherapy regimens are underway, which may extend the product’s lifecycle.

---

References

[1] Grand View Research. (2022). Anti-emetics Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2020). FENSOLVI (fosnetupitant/palonosetron) Approval Statement.
[3] MarketWatch. (2023). Global Anti-Emetic Drugs Market Analysis.